Herantis Pharma Oyj
HEL: HRTIS.HE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Helsinki
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Antti Vuolanto
- Employees
- 11
- Headquarters
- Espoo, Finland
- IPO year
- 2014
- Market cap
- €47.5M
- Website
- https://www.herantis.com
Loading HRTIS…
Loading profile data…Frequently asked questions about HRTIS
What does Herantis Pharma Oyj (HRTIS.HE) do?
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurode...
Where does HRTIS.HE trade?
Herantis Pharma Oyj (HRTIS.HE) trades on the NASDAQ Helsinki.
What sector is HRTIS.HE in?
Herantis Pharma Oyj (HRTIS.HE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Herantis Pharma Oyj?
Antti Vuolanto is the chief executive officer of Herantis Pharma Oyj (HRTIS.HE).
Where is Herantis Pharma Oyj headquartered?
Herantis Pharma Oyj is headquartered in Finland.
Does HRTIS.HE pay a dividend?
Herantis Pharma Oyj (HRTIS.HE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HRTIS.HE go public?
Herantis Pharma Oyj (HRTIS.HE) completed its initial public offering in 2014.